

50026/008001 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE Attorney Docket No. PATENT AND TRADEMARK OFFICE (MODIFIED) 09/132,521 Serial No. Yoshiyuki Nagai et al. Applicant INFORMATION DISCLOSURE August 11, 1998 Filing Date STATEMENT BY APPLICANT (Use several sheets if necessary) 4648 Group February 9, 1999 **IDS Filed** (37 CFR §1.98(b)) U.S. PATENTS Filing Date Class Subclass Patentee Issue Date Examiner's Patent Number (If Appropriate) Initials FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Translation Subclass Class Country or Document Publication Examiner's (Yes/No) Patent Office Date Number Initials **EPO** 09.09.1998 EP0863202A1 **EPO** 16.09.1998 EP0864645A1 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Kato et al, "The Paramyxovirus, Sendai Virus, V Protein Encodes a Luxury Function Required for Viral Pathogenesis," The EMBO Journal, 16:3 578-587 (1997). Kato et al , "Initiation of Sendai Virus Multiplication From Transfected cDNA or RNA with Negative or Positive Sense," Genes to Cells, 1:569-579 (1996). Kurotani, et al., "Sendai Virus C Proteins are Categorically Nonessential Gene Products but Silencing Their Expression Severely Impairs Viral Replication and Pathogenesis," Genes to Cells, 3:111-124 (1998). Moriya, et al., "Large Quantity Production With Extreme Convenience of Human SDF-1 α and SDF-1 β by a Sendai Virus Vector," FEBS Letters, 425:105-111 (1998). Tashiro, et al., "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins," Science, 261:600-602 (1993). Yu et al., "Sendai Virus-Based Expression of HIV-1 gp120: Reinforcement by the V(-) Version," Genes to Cells, 2 457-466 (1997). DATE CONSIDERED **EXAMINER** EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.